Longitudinal trends in hospitalization rates in patients with later-onset SMA (SMA) treated with nusinersen up to 4.5 years are discussed. Results from the CHERISH and SHINE studies are discussed.
Can Lecanemab Succeed Where Aduhelm Failed?
September 28th 2022The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.
Read More